Blog
RSS FeedPosted by Michael Wonder on 25 Jul 2024
New clot busting drug recommended by NICE set to save NHS millions of pounds
24 July 2024 - Giving a new clot busting drug to people who have had a stroke could help save the ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...
Posted by Michael Wonder on 18 Jul 2024
Rucaparib camsylate for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
8 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 18 Jul 2024
Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (review of previous guidance)
16 July 2024 - The Department of Health and Social Care has asked the NICE to review the guidance on ...
Posted by Michael Wonder on 16 Jul 2024
Elranatamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments
12 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 15 Jul 2024
Clinical benefit, reimbursement outcomes, and prices of FDA approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis
11 July 2024 - Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in ...
Posted by Michael Wonder on 10 Jul 2024
NICE recommends Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England in eligible adolescents and adults
10 July 2024 - Following approval of the European Commission (October 2023) and the MHRA (December 2023), lebrikizumab will be available ...
Posted by Michael Wonder on 10 Jul 2024
Lisocabtagene maraleucel for the treatment of adults with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
10 July 2024 - NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) ...
Posted by Michael Wonder on 09 Jul 2024
A new gene therapy, transformative cystic fibrosis medicines and an obesity jab included in guidance recommended during pre-election period
8 July 2024 - More than 20 pieces of draft and final guidance on a range of medicines and medical conditions ...
Posted by Michael Wonder on 04 Jul 2024
Lisocabtagene maraleucel for the treatment of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
4 July 2024 - NICE is unable to make a recommendation on the use of lisocabtagene maraleucel (Breyanzi) in the NHS ...
Posted by Michael Wonder on 04 Jul 2024
Zilucoplan for the treatment of patients with generalised antibody positive myasthenia gravis
4 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 03 Jul 2024
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection
27 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 29 Jun 2024
NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix
28 June 2024 - NICE has recommended CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) for immediate reimbursement by ...
Posted by Michael Wonder on 22 Jun 2024
Vertex announces extended long-term reimbursement agreement with NHS England for access to cystic fibrosis medicines Kaftrio, Symkevi and Orkambi
20 June 2024 - Agreement includes access to any future licence extensions. ...
Posted by Michael Wonder on 22 Jun 2024
NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia in adults
21 June 2024 - Kyowa Kirin is delighted by the decision made today by NICE to recommend Crysvita for the treatment ...